AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20478739 — intervention group
Group type: EXPERIMENTAL
Intervention: Method-of-limits (MLI) for thermal cold pain thresholds (CPT)
Number of subjects: 38
Study 20478739 — intervention group
Group type: EXPERIMENTAL
Intervention: Method-of-limits (MLI) for heat pain thresholds (HPT)
Number of subjects: 38
Study 18775821 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive biomedical health test including cardiovascular risk score (CVRS) followed by written advice and health consultations
Number of subjects: 2000
Study 18775821 — intervention group
Group type: COMPARATOR
Intervention: Control group answering questionnaires
Number of subjects: 2000
Study 16353930 — intervention group
Group type: EXPERIMENTAL
Intervention: True model (males not equal females)
Number of subjects: 50
Study 16353930 — intervention group
Group type: COMPARATOR
Intervention: False model (males = females)
Number of subjects: 50
Study 16353930 — intervention group
Group type: EXPERIMENTAL
Intervention: Both models
Number of subjects: 50
Study 12389657 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of subcutaneous fat layer with a running 3‐0 plain suture
Number of subjects: 327
Study 10429836 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir 4 mg intravenously in healthy participants and those with mild/moderate renal impairment
Number of subjects: 17
Study 10429836 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir 2 mg intravenously in participants with severe renal impairment
Number of subjects: 17
Study 10429836 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants receiving 4 mg zanamivir intravenously
Number of subjects: 17
Study 8538187 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-HPR at a dose of 200 mg po for five years in breast cancer study
Number of subjects: 2972
Study 8538187 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-HPR at a dose of 200 mg po for one year in basal cell carcinoma study
Number of subjects: 2972
Study 8538187 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-HPR at a dose of 200 mg po for one year in oral leukoplakia study
Number of subjects: 2972
Study 8538187 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment) in breast cancer study
Number of subjects: 2972
Study 8538187 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment) in basal cell carcinoma study
Number of subjects: 2972
Study 8538187 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment) in oral leukoplakia study
Number of subjects: 2972
Study 2147161 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (100 mg)
Number of subjects: 195
Study 2147161 — intervention group
Group type: COMPARATOR
Intervention: Combination of medroxyprogesterone acetate and tamoxifen (2 x 10 mg)
Number of subjects: 195
Study 38678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen syrup
Number of subjects: 22
Study 38678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30907624 — intervention group
Group type: EXPERIMENTAL
Intervention: LA Sprouts intervention (n=160)
Number of subjects: 290
Study 30907624 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=130)
Number of subjects: 290
Study 28430384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal naloxone 8 mg/0.4 ml
Number of subjects: 12
Study 28430384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal naloxone 16 mg/0.4 ml
Number of subjects: 12
Study 28430384 — intervention group
Group type: COMPARATOR
Intervention: Intravenous naloxone 1 mg/ml
Number of subjects: 12
Study 28430384 — intervention group
Group type: COMPARATOR
Intervention: Sublingual naloxone 16 mg/ml
Number of subjects: 12
Study 26589371 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential phospholipid (EPL) 1800 mg/day for 24 weeks, followed by 900 mg for 48 weeks
Number of subjects: 324
Study 26589371 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential phospholipid (EPL)
Number of subjects: 324
Study 24020649 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (18-24 mg) and Isoproterenol (20-30 mcg/min) administered intravenously after PVAI.
Number of subjects: 192
Study 24020649 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine and Isoproterenol administration with supplemental ablation for non-PV triggers inducing AF (group 1A).
Number of subjects: 192
Study 24020649 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine and Isoproterenol administration with supplemental ablation for non-PV foci that did not induce AF (group 1B).
Number of subjects: 192
Study 24020649 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine and Isoproterenol administration with no further ablation for non-PV foci that did not induce AF (group 1C).
Number of subjects: 192
Study 24020649 — intervention group
Group type: COMPARATOR
Intervention: Control group undergoing PVAI without drug challenge (group 2).
Number of subjects: 192
Study 21857276 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sciatic nerve block and continuous lumbar plexus blocks (group R, n = 19)
Number of subjects: 38
Study 21857276 — intervention group
Group type: COMPARATOR
Intervention: Single sciatic nerve block followed by saline infusion and continuous lumbar plexus block (group C, n = 19)
Number of subjects: 38
Study 19232032 — intervention group
Group type: EXPERIMENTAL
Intervention: S100 + M2000 (sitagliptin 50 mg b.i.d. + metformin 1000 mg b.i.d.)
Number of subjects: 1091
Study 19232032 — intervention group
Group type: EXPERIMENTAL
Intervention: S100 + M1000 (sitagliptin 50 mg b.i.d. + metformin 500 mg b.i.d.)
Number of subjects: 1091
Study 19232032 — intervention group
Group type: EXPERIMENTAL
Intervention: M2000 (metformin 1000 mg b.i.d.)
Number of subjects: 1091
Study 19232032 — intervention group
Group type: EXPERIMENTAL
Intervention: M1000 (metformin 500 mg b.i.d.)
Number of subjects: 1091
Study 19232032 — intervention group
Group type: EXPERIMENTAL
Intervention: S100 (sitagliptin 100 mg q.d.)
Number of subjects: 1091
Study 19232032 — intervention group
Group type: COMPARATOR
Intervention: PBO/M2000 (placebo switched to metformin 1000 mg b.i.d. at week 24)
Number of subjects: 1091
Study 17515742 — intervention group
Group type: EXPERIMENTAL
Intervention: Naprapathic manual therapy (Index Group)
Number of subjects: 409
Study 17515742 — intervention group
Group type: COMPARATOR
Intervention: Evidence-based care (Control Group)
Number of subjects: 409
Study 15024662 — intervention group
Group type: EXPERIMENTAL
Intervention: Tests of exertion of external force (lifting weight, pushing, pulling)
Number of subjects: 77
Study 15024662 — intervention group
Group type: EXPERIMENTAL
Intervention: Tests of rapid movements (jumping, sprinting, kicking)
Number of subjects: 77
Study 15024662 — intervention group
Group type: EXPERIMENTAL
Intervention: Tests of supporting body weight (chin‐ups, squats)
Number of subjects: 77
Study 11594926 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg remacemide hydrochloride
Number of subjects: 39
Study 11594926 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg remacemide hydrochloride
Number of subjects: 39
Study 11594926 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg remacemide hydrochloride
Number of subjects: 39
Study 11594926 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 39
Study 9561428 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge eating disorder treatment
Number of subjects: 88
Study 8076486 — intervention group
Group type: EXPERIMENTAL
Intervention: Carcinoembryonic antigen (CEA) monitoring every 3 months for two years, then every 6 months for the next three years.
Number of subjects: 311
Study 8076486 — intervention group
Group type: EXPERIMENTAL
Intervention: Carcinoembryonic antigen (CEA) monitoring for predicting hepatic metastases.
Number of subjects: 311
Study 8076486 — intervention group
Group type: EXPERIMENTAL
Intervention: Carcinoembryonic antigen (CEA) monitoring for predicting recurrent disease other than the liver.
Number of subjects: 311
Study 8076486 — intervention group
Group type: EXPERIMENTAL
Intervention: Carcinoembryonic antigen (CEA) as an indicator of subsequent recurrent disease.
Number of subjects: 311
Study 2644750 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (25‐50 mg bolus plus infusion, 5‐7.5 mg h‐1)
Number of subjects: 54
Study 143188 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment for 6 weeks
Number of subjects: 6
Study 143188 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 6
Study 30288964 — intervention group
Group type: EXPERIMENTAL
Intervention: Many barriers condition
Number of subjects: 86
Study 30288964 — intervention group
Group type: COMPARATOR
Intervention: Few barriers condition
Number of subjects: 86
Study 27696795 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Efficacy for Exercise (SEE)
Number of subjects: 514
Study 27696795 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Outcome Expectations for Exercise (POEE)
Number of subjects: 514
Study 27696795 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SEE
Number of subjects: 514
Study 27696795 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline POEE
Number of subjects: 514
Study 27696795 — intervention group
Group type: EXPERIMENTAL
Intervention: Important increases in physical activity level
Number of subjects: 514
Study 26101038 — intervention group
Group type: EXPERIMENTAL
Intervention: BEWARE intervention (body awareness training)
Number of subjects: 36
Study 26101038 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (physical therapy)
Number of subjects: 36
Study 24332353 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated software calculated approach
Number of subjects: 60
Study 24332353 — intervention group
Group type: COMPARATOR
Intervention: Manual target calculation
Number of subjects: 60
Study 23529989 — intervention group
Group type: EXPERIMENTAL
Intervention: Dunaliella bardawil capsules
Number of subjects: 34
Study 23529989 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch powder capsules)
Number of subjects: 34
Study 19632880 — intervention group
Group type: EXPERIMENTAL
Intervention: Low load cranio‐cervical flexion (C‐CF) training
Number of subjects: 46
Study 19632880 — intervention group
Group type: COMPARATOR
Intervention: Neck flexor strengthening exercises
Number of subjects: 46
Study 17719285 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent implantation
Number of subjects: 300
Study 17719285 — intervention group
Group type: COMPARATOR
Intervention: Zotarolimus-eluting stent implantation
Number of subjects: 300
Study 14962422 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levofloxacin (Quixin)
Number of subjects: 93
Study 14962422 — intervention group
Group type: COMPARATOR
Intervention: 0.3% ciprofloxacin (Ciloxan)
Number of subjects: 93
Study 11136688 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone levels in anterior interventricular vein (AIV)
Number of subjects: 68
Study 11136688 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone levels in coronary sinus (CS)
Number of subjects: 68
Study 11136688 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE activity levels in AIV
Number of subjects: 68
Study 11136688 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP levels in AIV
Number of subjects: 68
Study 11136688 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of aldosterone levels with LVEDP
Number of subjects: 68
Study 11136688 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of aldosterone levels with LV ejection fraction
Number of subjects: 68
Study 9184370 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight accelerated bacteriological evaluation (ABLE)
Number of subjects: 0
Study 9184370 — intervention group
Group type: COMPARATOR
Intervention: Empirical prescribing of antibiotics
Number of subjects: 0
Study 7882816 — intervention group
Group type: COMPARATOR
Intervention: Potato only for the first meal, Potato with fat for the second meal
Number of subjects: 9
Study 7882816 — intervention group
Group type: COMPARATOR
Intervention: Potato with fat for the first meal, Potato for the second meal
Number of subjects: 9
Study 7882816 — intervention group
Group type: COMPARATOR
Intervention: Potato only for the first meal, Potato only for the second meal
Number of subjects: 9
Study 7882816 — intervention group
Group type: COMPARATOR
Intervention: Potato with fat for the first meal, Potato with fat for the second meal
Number of subjects: 9
Study 7882816 — intervention group
Group type: COMPARATOR
Intervention: Potato with fat for the first meal, Potato without fat for the second meal
Number of subjects: 9
Study 3283783 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (median dose 125 mg daily)
Number of subjects: 141
Study 3283783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 3283783 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 141
Study 30217552 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose baclofen (30-270 mg/d)
Number of subjects: 23
Study 30217552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30217552 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose baclofen
Number of subjects: 23
Study 28025372 — intervention group
Group type: EXPERIMENTAL
Intervention: HPβCD-diclofenac
Number of subjects: 608
Study 28025372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608
Study 28025372 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac
Number of subjects: 608
Study 26499426 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition (underweight)
Number of subjects: 76
Study 26499426 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition (stunting)
Number of subjects: 76
Study 26499426 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition (wasting)
Number of subjects: 76
Study 26499426 — intervention group
Group type: EXPERIMENTAL
Intervention: Low weight for age
Number of subjects: 76
Study 23324599 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (VD) 1,000 IU daily for four months
Number of subjects: 116
Study 23324599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 21075373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 160mg daily for 8 weeks
Number of subjects: 53
Study 17554242 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 28
Study 16627414 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) only pacing
Number of subjects: 172
Study 16627414 — intervention group
Group type: COMPARATOR
Intervention: Biventricular (BiV) pacing
Number of subjects: 172
Study 14603195 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniaturized sequential device (CECT group)
Number of subjects: 100
Study 14603195 — intervention group
Group type: COMPARATOR
Intervention: Standard calf-length sequential IPC device (SCD group)
Number of subjects: 100
Study 15255249 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral DBS of the STN
Number of subjects: 12
Study 17216957 — intervention group
Group type: EXPERIMENTAL
Intervention: Egyptian version of Children's Health Locus of Control scale (40 statements, Yes/No format and 4-point Likert scale format)
Number of subjects: 930
Study 17216957 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Health Locus of Control scale
Number of subjects: 930
Study 7557512 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapiprazole 0.5% and Pilocarpine 2%
Number of subjects: 60
Study 7557512 — intervention group
Group type: COMPARATOR
Intervention: Dapiprazole 0.5%
Number of subjects: 60
Study 7557512 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine 2%
Number of subjects: 60
Study 2181858 — intervention group
Group type: EXPERIMENTAL
Intervention: Canola-oil-based diet (CAN)
Number of subjects: 0
Study 2181858 — intervention group
Group type: COMPARATOR
Intervention: Sunflower-oil-based diet (SUN)
Number of subjects: 0
Study 2181858 — intervention group
Group type: COMPARATOR
Intervention: Pre-experimental mixed-fat diet (Pre-exp)
Number of subjects: 0
Study 463054 — intervention group
Group type: EXPERIMENTAL
Intervention: Pop music during exercise on a bicycle ergometer
Number of subjects: 0
Study 463054 — intervention group
Group type: EXPERIMENTAL
Intervention: Pop music
Number of subjects: 0
Study 31971410 — intervention group
Group type: EXPERIMENTAL
Intervention: BWL + BIAS
Number of subjects: 72
Study 31971410 — intervention group
Group type: COMPARATOR
Intervention: BWL
Number of subjects: 72
Study 30694100 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic (Winclove 607 based on Omnibiotic® 10 AAD) for 28 days
Number of subjects: 0
Study 30694100 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 26856344 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute intermittent hypoxia (AIH) following ibuprofen pretreatment (800 mg)
Number of subjects: 9
Study 26856344 — intervention group
Group type: COMPARATOR
Intervention: Acute intermittent hypoxia (AIH) following placebo
Number of subjects: 9
Study 26856344 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen pretreatment (800 mg)
Number of subjects: 9
Study 26856344 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute intermittent hypoxia (AIH)
Number of subjects: 9
Study 25901619 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (3-dimensional MRI preoperative planning)
Number of subjects: 30
Study 25901619 — intervention group
Group type: COMPARATOR
Intervention: Traditional TKA (non-patient-specific instrumentation)
Number of subjects: 30
Study 23536584 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide morning injection
Number of subjects: 680
Study 23536584 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide evening injection
Number of subjects: 680
Study 23536584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 680
Study 21380982 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural education program over 6 weeks (6 sessions)
Number of subjects: 137
Study 21380982 — intervention group
Group type: COMPARATOR
Intervention: Usual school curriculum (Control Group)
Number of subjects: 137
Study 19272067 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathoracic impedance monitoring ON
Number of subjects: 532
Study 19272067 — intervention group
Group type: COMPARATOR
Intervention: Intrathoracic impedance monitoring OFF
Number of subjects: 532
Study 17240493 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-HepB-IPV vaccine coadministered with PCV and Hib
Number of subjects: 1008
Study 17240493 — intervention group
Group type: COMPARATOR
Intervention: Separate administration of DTaP, HepB, IPV, Hib, and PCV
Number of subjects: 1008
Study 15709331 — intervention group
Group type: EXPERIMENTAL
Intervention: One benchmark (100% MVC)
Number of subjects: 3
Study 15709331 — intervention group
Group type: EXPERIMENTAL
Intervention: Three benchmarks (25%, 75%, and 100% MVC)
Number of subjects: 3
Study 15709331 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 11571993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive, psycho-educational and supportive treatment
Number of subjects: 0
Study 11571993 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatment
Number of subjects: 0
Study 11571993 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 9305417 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (0.5 or 1.0 mg)
Number of subjects: 0
Study 9305417 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 8199756 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician A's practices
Number of subjects: 200
Study 8199756 — intervention group
Group type: COMPARATOR
Intervention: Physician B's practices
Number of subjects: 200
Study 31919583 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinoa biscuits (15 g daily for 4 weeks)
Number of subjects: 40
Study 31919583 — intervention group
Group type: COMPARATOR
Intervention: Control biscuits (iso-energetic, wheat flour)
Number of subjects: 40
Study 30594190 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain self-management course (2.5-h weekly sessions for 6 weeks)
Number of subjects: 121
Study 30594190 — intervention group
Group type: COMPARATOR
Intervention: Low-impact outdoor physical activity (1-h weekly sessions for 6 weeks)
Number of subjects: 121
Study 30594190 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain self-management course
Number of subjects: 121
Study 30594190 — intervention group
Group type: COMPARATOR
Intervention: Low-impact outdoor physical activity
Number of subjects: 121
Study 27055527 — intervention group
Group type: COMPARATOR
Intervention: Eslicarbazepine acetate monotherapy (1200 or 1600 mg once daily)
Number of subjects: 0
Study 27055527 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate monotherapy
Number of subjects: 0
Study 26643917 — intervention group
Group type: EXPERIMENTAL
Intervention: Online theory-based intervention (self-affirmation manipulation, health messages based on the theory of planned behaviour, implementation intention tasks)
Number of subjects: 2621
Study 26643917 — intervention group
Group type: EXPERIMENTAL
Intervention: Online theory-based intervention
Number of subjects: 2621
Study 26643917 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 2621
Study 23430004 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) training during the program
Number of subjects: 27
Study 23430004 — intervention group
Group type: COMPARATOR
Intervention: Control group (no VR training)
Number of subjects: 27
Study 23430004 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (VR and control)
Number of subjects: 27
Study 23430004 — intervention group
Group type: EXPERIMENTAL
Intervention: VR group
Number of subjects: 27
Study 20565345 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cholecalciferol 50,000 IU daily for 10 days
Number of subjects: 59
Study 20565345 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cholecalciferol 3000 IU daily for 30 days, followed by 1000 IU daily for 60 days
Number of subjects: 59
Study 18420876 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.125%
Number of subjects: 60
Study 18420876 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.2%
Number of subjects: 60
Study 16643492 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflux serous-lined extramural tunnel
Number of subjects: 60
Study 16643492 — intervention group
Group type: COMPARATOR
Intervention: Direct anastomosis
Number of subjects: 60